PIERRE FABRE MEDICAMENT

PIERRE FABRE MEDICAMENT is part of Pierre Fabre Laboratories, founded in 1962 and headquartered near Castres in southwest France. The group is the world's second-largest dermo-cosmetics company and one of Europe's leading pharmaceutical laboratories, developing and manufacturing both dermo-cosmetic and pharmaceutical products. Its pharmaceutical division works across five therapeutic areas: oncology, dermatology, rare diseases, primary care and family health.

The dermo-cosmetics portfolio includes Eau Thermale Avène, Klorane, Ducray, Dexeryl, A-Derma, René Furterer and Elgydium. Relevant technical domains span dermo-cosmetics, pharmaceuticals, oncology, dermatology, rare diseases, primary care, family health and skincare formulation. Nearly 90% of products are manufactured in France, reflecting a stated commitment to domestic production and quality.

The group reported revenue of €3.2 billion in 2025 and employs 71% of that revenue from international markets, operating from 43 locations and distributing products in approximately 130 territories.

Ownership is distinctive: the Pierre Fabre Foundation, recognised as a public-interest foundation by the French government, holds 86.3% of capital, while employees are the second-largest shareholder group with nearly 10%. Dividends fund 35 healthcare-access programmes in 22 of the world's least developed countries.